These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 9327897)

  • 21. [High blood pressure, catecholamines and the sympathetic nervous system. I. Molecular-pharmacological insights].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1975 Jan; 119(4):144-53. PubMed ID: 236521
    [No Abstract]   [Full Text] [Related]  

  • 22. Mao-B inhibitor know-how: back to the pharm.
    Burke WJ
    Neurology; 2009 Dec; 73(23):2048; author reply 2048. PubMed ID: 19996086
    [No Abstract]   [Full Text] [Related]  

  • 23. Catechol-O-methyltransferase and monoamine oxidase-A polymorphisms and treatment response to typical and atypical neuroleptics.
    Nolan KA; Czobor P; Citrome LL; Krakowski M; Lachman HM; Kennedy JL; Ni X; Lieberman J; Chakos M; Volavka J
    J Clin Psychopharmacol; 2006 Jun; 26(3):338-40. PubMed ID: 16702905
    [No Abstract]   [Full Text] [Related]  

  • 24. [Adrenergic amines and monoaminoxidases in essential arterial hypertension].
    Sicuteri F; Buffoni F; Michelacci S; Del Bene E
    Acta Vitaminol Enzymol; 1969; 23(1):45-63. PubMed ID: 4896867
    [No Abstract]   [Full Text] [Related]  

  • 25. Rasagiline (Azilect) for Parkinson's disease.
    Med Lett Drugs Ther; 2006 Dec; 48(1249/1250):97-9. PubMed ID: 17149358
    [No Abstract]   [Full Text] [Related]  

  • 26. CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease.
    Zhu BT
    Int J Mol Med; 2004 Mar; 13(3):343-53. PubMed ID: 14767563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Localization of catecholamine degrading enzymes in the rat heart.
    Lowe MC; Creveling CR
    Proc West Pharmacol Soc; 1978; 21():473-4. PubMed ID: 693535
    [No Abstract]   [Full Text] [Related]  

  • 28. Other pharmacological treatments for motor complications and dyskinesias.
    Waters C
    Mov Disord; 2005; 20 Suppl 11():S38-44. PubMed ID: 15822104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
    Chazot PL
    Curr Opin Investig Drugs; 2007 Jul; 8(7):570-9. PubMed ID: 17659477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Personality traits of aggression-submissiveness and perfectionism associate with ABO blood groups through catecholamine activities.
    Hobgood DK
    Med Hypotheses; 2011 Aug; 77(2):294-300. PubMed ID: 21601990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.
    Delumeau JC; Bentué-Ferrer D; Gandon JM; Amrein R; Belliard S; Allain H
    J Neural Transm Suppl; 1994; 41():259-66. PubMed ID: 7931235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [What strategies are recommended for early stage disease? Other treatments].
    Damier P
    Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():105-8. PubMed ID: 10916044
    [No Abstract]   [Full Text] [Related]  

  • 33. Membrane-bound catechol-O-methyltransferase: a reevaluation of its role in the O-methylation of the catecholamine neurotransmitters.
    Roth JA
    Rev Physiol Biochem Pharmacol; 1992; 120():1-29. PubMed ID: 1519017
    [No Abstract]   [Full Text] [Related]  

  • 34. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
    Naoi M; Maruyama W
    Expert Rev Neurother; 2009 Aug; 9(8):1233-50. PubMed ID: 19673610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives.
    Cesura AM; Borroni E; Gottowik J; Kuhn C; Malherbe P; Martin J; Richards JG
    Adv Neurol; 1999; 80():521-8. PubMed ID: 10410766
    [No Abstract]   [Full Text] [Related]  

  • 37. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
    Bainbridge JL; Page RL; Ruscin JM
    Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases.
    Ucar G; Gokhan N; Yesilada A; Bilgin AA
    Neurosci Lett; 2005 Jul; 382(3):327-31. PubMed ID: 15925113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MAO-B inhibitor know-how: back to the pharm.
    Lewitt PA
    Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
    [No Abstract]   [Full Text] [Related]  

  • 40. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition.
    Klegeris A; McGeer PL
    Exp Neurol; 2000 Dec; 166(2):458-64. PubMed ID: 11085911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.